BACKGROUND: The use of biomarkers has become a major component of clinical trial design. In Huntington's disease (HD), quantifying the amount of huntingtin protein (HTT) in patient cerebrospinal fluid (CSF) has served as a pharmacodynamic readout for HTT-lowering therapeutic approaches and is a potential disease progression biomarker. To date, an ultrasensitive immunoassay to quantify mutant HTT protein (mHTT) has been used, but additional assays are needed to measure other forms of HTT protein. OBJECTIVE: We aimed to develop an ultrasensitive immunoassay to quantify HTT protein in a polyglutamine length-independent manner (mHTT and non-expanded wild type HTT combined) in control and HD participant CSF samples. METHODS: An ultrasensitive, bead-based, single molecule counting (SMC) immunoassay platform was used for the detection of HTT protein in human CSF samples. RESULTS: A novel ultrasensitive SMC immunoassay was developed to quantify HTT protein in a polyglutamine length-independent manner and shown to measure HTT in both control and HD participant CSF samples. We validate the selectivity and specificity of the readout using biochemical and molecular biology tools, and we undertook a preliminary analytical qualification of this assay to enable its clinical use. We also used this novel assay, along with the previously described mHTT assay, to analyze CSF from control and HD participants. The results of this preliminary set suggests that correlation is present between mHTT and the polyglutamine length-independent HTT levels in human CSF. CONCLUSION: We have developed a novel ultrasensitive immunoassay that is able to quantify HTT protein in a polyglutamine length-independent manner in control and HD participant CSF.
BACKGROUND: The use of biomarkers has become a major component of clinical trial design. In Huntington's disease (HD), quantifying the amount of huntingtin protein (HTT) in patient cerebrospinal fluid (CSF) has served as a pharmacodynamic readout for HTT-lowering therapeutic approaches and is a potential disease progression biomarker. To date, an ultrasensitive immunoassay to quantify mutant HTT protein (mHTT) has been used, but additional assays are needed to measure other forms of HTT protein. OBJECTIVE: We aimed to develop an ultrasensitive immunoassay to quantify HTT protein in a polyglutamine length-independent manner (mHTT and non-expanded wild type HTT combined) in control and HD participant CSF samples. METHODS: An ultrasensitive, bead-based, single molecule counting (SMC) immunoassay platform was used for the detection of HTT protein in human CSF samples. RESULTS: A novel ultrasensitive SMC immunoassay was developed to quantify HTT protein in a polyglutamine length-independent manner and shown to measure HTT in both control and HD participant CSF samples. We validate the selectivity and specificity of the readout using biochemical and molecular biology tools, and we undertook a preliminary analytical qualification of this assay to enable its clinical use. We also used this novel assay, along with the previously described mHTT assay, to analyze CSF from control and HD participants. The results of this preliminary set suggests that correlation is present between mHTT and the polyglutamine length-independent HTT levels in human CSF. CONCLUSION: We have developed a novel ultrasensitive immunoassay that is able to quantify HTT protein in a polyglutamine length-independent manner in control and HD participant CSF.
Authors: Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker Journal: Pharm Res Date: 2003-11 Impact factor: 4.200
Authors: Melanie J Bennett; Kathryn E Huey-Tubman; Andrew B Herr; Anthony P West; Scott A Ross; Pamela J Bjorkman Journal: Proc Natl Acad Sci U S A Date: 2002-08-22 Impact factor: 11.205
Authors: Amber L Southwell; Stephen E P Smith; Tessa R Davis; Nicholas S Caron; Erika B Villanueva; Yuanyun Xie; Jennifer A Collins; Min Li Ye; Aaron Sturrock; Blair R Leavitt; Adam G Schrum; Michael R Hayden Journal: Sci Rep Date: 2015-07-15 Impact factor: 4.379
Authors: Wolfgang Reindl; Barbara Baldo; Jana Schulz; Isabell Janack; Ilka Lindner; Markus Kleinschmidt; Yalda Sedaghat; Christina Thiede; Karsten Tillack; Christina Schmidt; Isabell Cardaun; Tom Schwagarus; Frank Herrmann; Madlen Hotze; Georgina F Osborne; Simone Herrmann; Andreas Weiss; Celina Zerbinatti; Gillian P Bates; Jonathan Bard; Ignacio Munoz-Sanjuan; Douglas Macdonald Journal: PLoS One Date: 2019-03-26 Impact factor: 3.240
Authors: Valentina Fodale; Roberta Pintauro; Manuel Daldin; Roberta Altobelli; Maria Carolina Spiezia; Monica Bisbocci; Douglas Macdonald; Alberto Bresciani Journal: Sci Rep Date: 2020-12-17 Impact factor: 4.379
Authors: Davina J Hensman Moss; Nicola Robertson; Ruth Farmer; Rachael I Scahill; Salman Haider; Michela A Tessari; Geraldine Flynn; David F Fischer; Edward J Wild; Douglas Macdonald; Sarah J Tabrizi Journal: PLoS One Date: 2017-12-22 Impact factor: 3.240